Drug intelligence / Profile preview

DWC20155 + DWC20156 + DWC20162

Development stage: Discontinued
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWC20155 + DWC20156 + DWC20162 is a combination of three investigational small molecule compounds developed by Daewoong Pharmaceutical, evaluated primarily in clinical drug-drug interaction studies in healthy volunteers. These compounds have been investigated for potential gastrointestinal indications, with primary research goals including characterization of their pharmacokinetic interactions. No details on their precise chemical identities or therapeutic mechanisms have been disclosed in public sources[1][3][4][5].

Beyond the preview

Go deeper on DWC20155 + DWC20156 + DWC20162.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC20155 + DWC20156 + DWC20162.

Explore the full profile